|| Checking for direct PDF access through Ovid
Paliperidone prolonged release (PR) is a new product licensed for the treatment of schizophrenia. It is the active metabolite of risperidone, a drug that has been successfully used in the treatment of schizophrenia and mood disorder. Paliperidone PR has a unique pharmacological delivery mechanism that may incur benefits for particular patients diagnosed with schizophrenia. Studies investigating paliperidone PR are reviewed along with implications for its use by nurse prescribers and those nurses who monitor the use of medication for people with psychosis.